How could a gene that causes one type of ALS be switched off? In episode 87, Tim Miller from the Washington University in St. Louis discusses his research into therapies that target the single strands of DNA or RNA which cause many cases of amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease. His article “Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS” was published with multiple co-authors on July 9th 2020 in the New England Journal of Medicine.
Websites and other resources
- NEJM editorial on Tim’s study
- Tim’s lab website
- Video of Tim discussing new therapies for ALS:
🔊 Access bonus content here.
Support us for as little as $1 per month at Patreon. Cancel anytime.
We’re not a registered tax-exempt organization, so unfortunately gifts aren’t tax deductible.
Hosts / Producers
Ryan Watkins & Doug Leigh
How to Cite
What’s The Angle? by Shane Ivers